New ACR Breast Cancer Screening Guidelines call for earlier and more-intensive screening for high-risk women

Other Notable Updates:   New American College of Radiology® (ACR®) breast cancer screening guidelines now call for all women &mdas...

May 04, 2023 | Thursday | News
China Phase II Clinical Study of Osemitamab Completes Enrollment for First-Line Gastric Cancer Treatment

Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, resear...

May 03, 2023 | Wednesday | News
EirGenix's EG1206A Meets Phase 1 Trial Objectives as Breast Cancer Biosimilar

EG1206A is a biosimilar drug of the second-generation HER2-positive antibody drug Perjeta® (pertuzumab). EG1206A has a unique binding mechanism for HER...

May 03, 2023 | Wednesday | News
Genomic Urine Test Detects Bladder Cancer from DNA Up to 12 Years Before Clinical Signs and Symptoms Appear

A new genomic urine test can help doctors accurately predict bladder cancer as many as 12 years before clinical signs and symptoms emerge and long before a...

May 02, 2023 | Tuesday | News
Curasight and Curium announce global partnership for uTRACE® in prostate cancer

Curasight to develop its proprietary uTRACE® PET imaging technology to obtain regulatory approval in EU and USA, with Curium responsible for man...

May 02, 2023 | Tuesday | News
Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture Financing

Rakovina Therapeutics also announced that it will issue approximately thirty (30) unsecured $50,000 convertible debenture units to a select group of i...

May 02, 2023 | Tuesday | Company results
Could Tumoroids Solve the Problem of High Attrition in Cancer Trials?

There is growing recognition that the experimental model systems used in many cancer research projects, which include 2D cell cultures, patient-derived xen...

May 01, 2023 | Monday | News
Pfizer and Astellas' XTANDI® Combo Proves Effective in Reducing Prostate Cancer Metastasis Risk by 58%: Phase 3 EMBARK Trial Results Revealed

Data from Phase 3 EMBARK trial to be presented as a plenary session during the 2023 American Urological Association Annual Meeting Res...

May 01, 2023 | Monday | News
Janssen Reports First Results of TAR-200 and Cetrelimab Study in Non-Muscle-Invasive Bladder Cancer

Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need T...

May 01, 2023 | Monday | News
Brenus Pharma Unveils Preclinical Results for Promising New Cancer Drug STC-10101

Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Ph...

April 28, 2023 | Friday | News
How CRISPR Is Changing Cancer Research and Treatment

But a game-changer occurred in 2013, when several researchers showed that a gene-editing tool called CRISPR could alter the DNA of human cells like a v...

April 27, 2023 | Thursday | News
VySpine Announces FDA Clearance for UniVy OsteoVy-Ti Cervical IBF with NanoVy-HA

The UniVy OsteoVy-Ti NanoVy-HA Cervical IBF System features VySpine's NanoVy-HA technology in partnership with Promimic AB. NanoVy-HA is a process in which...

April 26, 2023 | Wednesday | Regulatory
Agilent and Theragen Bio collaborate to boost cancer genomic profiling through bioinformatic solutions in South Korea.

Agilent Technologies Inc. (NYSE: A) announced the recent signing of a Memorandum of Understanding (MOU) with Theragen Bio in South Korea to boos...

April 26, 2023 | Wednesday | News
Foundational LCD Covers Select mdx for Prostate Cancer

Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report this very positive and important development for mdxhealth. The quality ...

April 20, 2023 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close